Asunto(s)
Productos Biológicos/efectos adversos , Linfoma de Células B/epidemiología , Linfoma Cutáneo de Células T/epidemiología , Neoplasias Cutáneas/epidemiología , Biopsia , Bases de Datos Factuales/estadística & datos numéricos , Estudios de Seguimiento , Francia/epidemiología , Humanos , Linfoma de Células B/inducido químicamente , Linfoma de Células B/diagnóstico , Linfoma de Células B/patología , Linfoma Cutáneo de Células T/inducido químicamente , Linfoma Cutáneo de Células T/diagnóstico , Linfoma Cutáneo de Células T/patología , Farmacovigilancia , Pitiriasis Rubra Pilaris/tratamiento farmacológico , Psoriasis/tratamiento farmacológico , Estudios Retrospectivos , Piel/patología , Neoplasias Cutáneas/inducido químicamente , Neoplasias Cutáneas/diagnóstico , Neoplasias Cutáneas/patologíaRESUMEN
BACKGROUND: Survival can be threatened in certain forms of systemic sclerosis (SSc) so clear prognostic factors are needed. OBJECTIVES: The aim of this meta-analysis was to assess the association between the presence of digital ulcers (DUs) and mortality in SSc. METHODS: We performed a systematic review and meta-analysis in the Pubmed and Scopus databases from the earliest records to May 2017. Two research strategies were performed: « systemic sclerosis ¼ and « digital ulcers ¼ (strategy A); « systemic sclerosis ¼ and « mortality ¼ (strategy B). The primary outcome was the mortality associated with the presence of DUs in patients with SSc. RESULTS: The literature search identified 1473 citations. Fifty-nine studies were examined for full text. Ten articles were included for the meta-analysis. SSc patients with DUs had an increased pooled mortality risk: RR = 1.53 (IC 95%: [1.23-1.90]). CONCLUSIONS: This meta-analysis revealed a higher mortality in SSc patients with associated DUs. Having DUs may be a predictive factor of developing organ involvement such as pulmonary or cardiovascular events that could be associated with poor survival. It suggests that early screening of DUs in SSc patients is important to identify patients most at risk of poor survival.
